{
  "@context": "https://frontierpicks.com/schemas/dossier.v1.json",
  "ticker": "ODD",
  "name": "ODDITY Tech Ltd.",
  "url": "https://frontierpicks.com/dossiers/ODD/",
  "json_url": "https://frontierpicks.com/dossiers/ODD.json",
  "status": "DORMANT",
  "current_conviction": "LOW",
  "graded_conviction": null,
  "archetype": {
    "code": "a5",
    "n": 5
  },
  "current_thesis": "Compounder narrative is dead (Q1 revenue -26%, first orders -50%) and the drift continued on no news at all: $14.12 on 2026-08-07 to $13.22 on 2026-08-21, now sitting on the $13 shelf. The 2026-09-09 pre-market Q2 print is the only dated event and the whole binary — first-order trend, CPA direction, and whether the FY2026 positive-adjusted-EBITDA guide survives.",
  "invalidation_trigger": "A weekly close below $13 abandons the post-crash shelf under the 2026-08-21 close of $13.22 and re-opens the $9.25 area; secondary condition: the 2026-09-09 Q2 print shows first orders still down more than 40% YoY with CPA unimproved, or the FY2026 positive-adjusted-EBITDA guide is withdrawn.",
  "catalyst_date": "2026-09-09",
  "outcome": "OPEN",
  "outcome_date": null,
  "invalidation_fired": null,
  "themes": [
    "consumer-discretionary-rotation",
    "precision-biotech-therapeutics"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "Foreign private issuer (Israel): reports via 6-K/20-F, not 10-Q — quarterly detail is thinner than a US domestic filer's.",
    "Dual-class structure: listed Class A versus founder-held Class B super-voting shares; public holders do not control the vote.",
    "Reporting cadence slipped twice in 2026 — Q1 on 2026-06-02 versus a prior early-May pattern, Q2 to 2026-09-09 versus 2025-08-04 for Q2 2025.",
    "Buyback authorization had $167.3M remaining as of the Q1 2026 report; the issuer is an active bidder in its own Class A stock.",
    "The 'largest advertising partner' behind the CPA blowout has never been named by the company, so the claim cannot be cross-checked externally.",
    "Consensus-target screens for ODD disagree materially post-crash (values from $8 to stale figures above $60); check the named post-Q1 targets rather than an aggregate."
  ],
  "body_markdown": "## Current Thesis\nNothing dated has happened since the last note, and the tape drifted anyway: $14.12 on 2026-08-07 to **$13.22 on 2026-08-21**, with the most recent company announcement still the 2026-07-22 press release scheduling Q2 2026 results for **2026-09-09** before the US open. The compounder story that priced the $63.68 52-week high is finished — Q1 2026 revenue $197.9M (-26% YoY), first orders -50%, gross margin 69.7% versus 74.9%, all reported 2026-06-02 — and the replacement story, normalization of the IL MAKIAGE paid-acquisition engine, still has no evidence attached to it until the September print. What changed in the last two weeks is the valuation gap: at $14.12 the stock traded above four of five published post-Q1 targets; at $13.22 it sits between Truist's $12 and Evercore ISI's $15, so the de-rating toward the Street has largely happened without any new disclosure. The remaining question is binary and dated.\n\n**The narrative is dead.** The evidence is the structure, not the mood — 79.2% below the $63.68 52-week high, consensus target cut from $17.33 to $10.09 after 2026-06-02, Goldman Sachs to Sell and KeyBanc to Sector Weight in the same window, and a lower-high sequence from ~$17.88 on 2026-07-03 through $14.12 and $13.22. A dead narrative can still produce a violent print reaction; it has not produced a base.\n\n## Bull Case\n- **Q1 2026 revenue $197.9M, -26% YoY (reported 2026-06-02)** landed inside the pre-announced ~-30% cut — the single datapoint the normalization camp anchors on.\n- **Repeat orders -15% against first orders -50% (Q1 2026 disclosure).** The installed base held; management attributed the shortfall to one advertising partner's auction dynamics rather than to demand.\n- **$667.4M in cash, equivalents and investments plus a $350M undrawn credit facility at Q1 2026.** Solvency is not the debate at a mid-hundreds-of-millions market capitalisation.\n- **The issuer is a standing bidder in its own stock:** ~6.1M Class A shares repurchased for $82.3M in Q1 2026, with $167.3M of authorization remaining as of 2026-06-02.\n- **2026-06-12: $50M face of 0% exchangeable notes due 2030 retired for $35M** — roughly 70 cents on the dollar, and it removes part of the 2030 dilution overhang.\n- **FY2026 adjusted EBITDA is still guided positive** despite Q1 adjusted EBITDA of -$7.0M, which requires an H2 swing management has not yet withdrawn.\n- **Prior-cycle economics were real:** FY2025 adjusted EBITDA $163M, Q4 2025 revenue +24% YoY (reported February 2026).\n- **Methodiq**, launched 2025-11-18, was framed on the Q1 2026 call as a ~$25M revenue contributor in 2026 per transcript coverage — small against a $197.9M quarter, but it is the only growth line management has quantified.\n\n## Bear Case\n- **Q2 2026 was guided to -25% to -30% YoY revenue at the Q1 report.** The 2026-09-09 print is not scheduled to show growth; only the shape of the decline is contested.\n- **The -50% first-order hole compounds forward.** DTC repeat revenue is a function of prior new-customer cohorts, so a lost H1 2026 acquisition year pressures 2027 repeat revenue even if customer-acquisition cost normalizes immediately.\n- **Margin went with the cohorts:** 69.7% gross margin and a $21.4M net loss in Q1 2026, against 74.9% a year earlier.\n- **The Street has not underwritten a recovery.** Post-Q1 targets: Barclays $8, Morgan Stanley $10, Jefferies $10.25, Truist $12, Evercore ISI $15. A consensus screen retrieved 2026-08-22 showed a 7-analyst average of $11.07, high $16, low $8 — still below the 2026-08-21 close.\n- **No new information for a month.** The last dated company item is 2026-07-22. Price fell from $14.12 to $13.22 across 2026-08-07 to 2026-08-21 on no disclosure at all, which is supply meeting a thin bid.\n- **The reporting calendar slipped twice in 2026** — Q1 to 2026-06-02 against a prior early-May cadence, Q2 to 2026-09-09 against 2025-08-04 for Q2 2025 — without a disclosed reason.\n- **The advertising partner has never been named**, so the central causal claim in the bull case cannot be verified outside management commentary.\n\n## Setup & Price Structure\nReference points as of the 2026-08-21 close of **$13.22**: 79.2% below the $63.68 52-week high, a three-month price change of +7.3%, RSI(14) at 38.2. The three-month window now opens after the initial de-rating, so that +7.3% describes churn inside a roughly $9.25–$17.88 range rather than recovery. The July sequence is unambiguous: ~$17.88 on 2026-07-03, $14.12 on 2026-08-07, $13.22 on 2026-08-21 — three lower observations into an event.\n\nThe $13 area is the last visible shelf between the current close and the $9.25 bounce origin from the post-Q1 washout. RSI at 38.2 is mid-range: no oversold flush, no trend. There is no base here to fail; there is a drift into a pre-market print.\n\n**Crowding and positioning observables, stated as filed:**\n- **Earnings gap risk is 18 days out** as of 2026-08-22 — 2026-09-09 before the US open, call at 8:30 a.m. ET (announced 2026-07-22). Pre-market release means the reaction is a gap, not an intraday process.\n- Each filing states the sale covers tax-withholding obligations, so the pattern is mechanical vesting rather than discretionary distribution — the observable is the recurrence and the RSU vest date, not a sentiment signal.\n- **The issuer's own bid is the identifiable non-discretionary buyer**: $167.3M of buyback authorization remained at 2026-06-02 after $82.3M was spent in Q1 into a quarter with -$7.0M adjusted EBITDA.\n- **Retail-sentiment coverage has thinned rather than clustered.** No ODD headline appeared on the tape between 2026-07-22 and 2026-08-21 in the sources checked; a name 79% off its high with no news flow has no fresh bid to crowd.\n\n## Catalyst Calendar (next 30 days)\n- **2026-09-09** — Q2 2026 results, released before US market open, conference call 8:30 a.m. ET (date announced 2026-07-22). Resolves whether Q2 revenue landed inside the -25% to -30% guide, the first-order trajectory against Q1's -50%, whether repeat orders decelerated past -15%, the direction of customer-acquisition cost, and whether the FY2026 positive-adjusted-EBITDA guide survives.\n- **2026-09-09** — updated cash and buyback disclosure in the same release. Q1 showed $667.4M in cash, equivalents and investments and $167.3M of remaining authorization; the Q2 figures show whether the repurchase pace continued through a loss-making half.\n- No other dated company event falls between 2026-08-22 and 2026-09-21 on the investor-relations calendar as of 2026-08-22.\n- *Outside the window:* Q3 2026 results, ~2026-11 (est.), given a calendar that has already moved twice this year.\n\n## What Would Change Our Mind\nThe structure that has to give way first is the $13 shelf — the last horizontal reference between the 2026-08-21 close of $13.22 and the $9.25 area the July bounce started from. **A weekly close below $13** abandons it and re-opens that lower zone; a print-driven gap through it on 2026-09-09 would be the same event with a cause attached.\n\nOn the other side, the datapoints that would force a rebuild of the frame are all in the 2026-09-09 release: Q2 revenue declining less than the guided -25%, first orders improving to better than -25% YoY from Q1's -50%, customer-acquisition cost explicitly down sequentially, and the FY2026 positive-adjusted-EBITDA guide reaffirmed with an H2 bridge. A weekly close back above the 2026-07-03 high near $17.88 would mark the market pricing that recovery ahead of the evidence.\n\nThe condition that would make the name uninteresting rather than wrong: 2026-09-09 comes and goes with revenue inside the guide, no first-order improvement, and the FY guide quietly softened — a slow bleed with no dated event until roughly November.\n\n## Correlation Notes\n- **The stated cause of the collapse is an ad-auction dislocation, not beauty demand.** Read-throughs therefore come from large advertising platforms' pricing commentary before they come from beauty peers; a DTC comparable's strong quarter does not falsify the ODD story, and vice versa.\n- **Foreign private issuer, Israel-domiciled.** Reports on 6-K/20-F rather than 10-Q, so quarterly disclosure is thinner than a US domestic filer's and there is no quarterly cash-flow statement of the usual granularity to check the buyback against.\n- **Dual-class structure:** listed Class A versus founder-held Class B super-voting shares. Buybacks shrink the Class A float while leaving voting control unchanged, so float compression is not the same as control change.\n- **Consumer-discretionary beta is present but secondary.** The 2026 drawdown from $63.68 to $13.22 is company-specific — it dates to the pre-announcement and the 2026-06-02 print, not to a sector move — so the name should be expected to trade on its own release schedule rather than with a rotation.",
  "first_seen": "2026-07-12",
  "last_analyzed": "2026-08-22T11:09:24+00:00",
  "last_synthesized": "2026-08-22",
  "last_update_source": "watchlist_research",
  "license": "Content © FrontierPicks. Cite the canonical URL."
}